CWM
VRTX icon

Compass Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Compass Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$34.8K – 412
2023
Q3 		$34.8K Hold
100
– – 0.01% 269
2023
Q2 		$35.2K Hold
100
– – 0.01% 279
2023
Q1 		$31.5K Hold
100
– – 0.01% 287
2022
Q4 		$28.9K Buy
+100
New +$30.5K 0.01% 285

Other funds holding VRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Compass Wealth Management's VRTX Position: Q4 2023 in Review

Compass Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 100 shares — an estimated $34.8K sold.

Compass Wealth Management first reported a position in VRTX in Q4 2022 and held it in 4 quarters. The position peaked at $35.2K in Q2 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

  • Compass Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Compass Wealth Management sold 100 Vertex Pharmaceuticals shares in Q4 2023, an estimated $34.8K.
  • Compass Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Compass Wealth Management's Vertex Pharmaceuticals position peaked at $35.2K in Q2 2023.
  • 1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Compass Wealth Management's 13F filing for Q4 2023, filed 4 Jan 2024.